Lidocaína 1% Braun

Lidocaine, the active ingredient in Lidocaína 1% Braun, is a local anesthetic presented as a 1% (10 mg/mL) solution for epidural, intradermal and subcutaneous use. It provides reversible nerve‑impulse blockade to produce temporary loss of sensation during surgical and diagnostic procedures.

GNH USA supplies Lidocaína 1% Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lidocaine is a local anesthetic used to achieve temporary loss of sensation in targeted tissues.

Epidural anesthesia: provides analgesia for labor, cesarean sections and lower‑body surgeries. Intradermal anesthesia: enables painless skin biopsies, dermal filler placement and minor dermatologic procedures. Subcutaneous anesthesia: facilitates minor surgical incisions and suturing by numbing the tissue beneath the skin.

Lidocaine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Tingling or numbness at the injection site - Mild swelling or erythema around the administration area - Dizziness or light‑headedness - Metallic taste in the mouth

Serious or Rare Side Effects: - Cardiac arrhythmias, including ventricular tachycardia - Severe hypotension or cardiovascular collapse - Seizures or central nervous system toxicity - Allergic reactions such as rash, bronchospasm, or anaphylaxis - Methemoglobinemia leading to cyanosis - Respiratory depression requiring airway support

Before using Lidocaína 1% Braun, consider the following safety measures.

Allergy assessment: verify no known hypersensitivity to lidocaine or other amide‑type anesthetics. Cardiac risk: use caution in patients with existing heart block, arrhythmias, or severe conduction disorders. Dose limitation: avoid exceeding recommended cumulative doses to reduce toxicity risk. CNS monitoring: observe for signs of central nervous system excitation or depression during and after administration. Hepatic function: adjust dosing in patients with significant liver impairment as metabolism may be reduced. Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Lidocaine can interact with several medicines, altering its plasma concentration or enhancing toxicity.

Major Interactions (Avoid): - Amiodarone: potent CYP3A4 inhibition increases lidocaine levels. - Cimetidine: reduces hepatic clearance, raising systemic exposure. - Erythromycin: may elevate plasma concentrations through metabolic inhibition. - Mexiletine: additive sodium‑channel blockade can precipitate toxicity. - Class I antiarrhythmics (e.g., quinidine, procainamide): synergistic cardiac effects.

Moderate Interactions (Monitor Closely): - Beta‑adrenergic blockers: may mask early signs of lidocaine toxicity. - Calcium channel blockers: can enhance negative inotropic effects. - Diuretics (especially thiazides): may lower serum albumin, increasing free drug. - General anesthetics (e.g., propofol, volatile agents): monitor for additive CNS depression. - Opioids: heightened risk of respiratory depression when combined.